{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"106","upperLimit":"290","value":"182"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"}],"units":"Participants"}],"description":"Time to progression (≥50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions) was defined as the duration from the date of the first study drug dose to the date of relapse or progression as reported by the independent review committee and was determined using Kaplan-Meier product-limit estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received romidepsin 14 mg/m\\^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.","id":"OG000","title":"Romidepsin"}],"paramType":"MEDIAN","populationDescription":"Histopathologically-Confirmed Population. Censoring for patients who did not have a date of progression was conducted based on last assessment reported for the patient.","reportingStatus":"POSTED","timeFrame":"Response was assessed after every 2 cycles of treatment and at completion of therapy, up until 30 September 2012 (data cutoff for analysis). Maximum duration on study was 1931 days.","title":"Time to Disease Progression","type":"SECONDARY","unitOfMeasure":"days"}